Resumen
Antibodies targeting CD38, a NAD+-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD+ to enhance the efficacy of anti-CD38-based immunotherapies in MM.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 9-12 |
Número de páginas | 4 |
Publicación | Trends in Cancer |
Volumen | 6 |
N.º | 1 |
DOI | |
Estado | Published - ene. 2020 |
Nota bibliográfica
Funding Information:This work was supported by grants from the Canadian Cancer Society (CRS), the Canadian Cancer Society Research Institute (CCSRI), the Canadian Institutes of Health Research (CIHR), and the Beatrice Hunter Cancer Research Institute (BHCRI) to S.A.G. B.E.K. is a trainee in the Cancer Research Training Program (CRTP) of the BHCRI with funding from the Terry Fox Research Institute (TFRI). S.A.G. is supported by Dalhousie Medical Research Foundation (DMRF).
Publisher Copyright:
© 2019
ASJC Scopus Subject Areas
- Oncology
- Cancer Research